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Dendritic cells (DCs) are key mediators of immune function
through robust and tightly regulated presentation of antigen in
the context of the MHC Class II. MHC Class II expression is
controlled by the transactivator CIITA. CIITA expression in
conventional DCs is uniquely dependent on an uncharacterized
myeloid cell-specific promoter, CIITApI. We now identify in
vivo the promoter structure and factors regulating CIITApI. In
immature DCs transcription requires binding of PU.1, IRF8,
NFB, and Sp1 to the promoter. PU.1 binds independently at
one site and in a required heterodimer with IRF8 at a composite
element.DCs from IRF8-nullmice have anunoccupiedCIITApI
promoter that can be rescued by reconstitution with IRF8 in
vitro. Furthermore, mutation of either PU.1 site or the IFR8 site
inhibits transcriptional activation. In vivo footprinting and
chromatin immunoprecipitation reveals that DC maturation
induces complete disassociation of the bound activators paral-
leled by recruitment of PRDM1/Blimp-1 to the promoter.
PRDM1 is a transcriptional repressor with essential roles in B
cells, T cells, NK cells, and DCs. We show that PRDM1 co-re-
pressors, G9a and HDAC2, are recruited to CIITApI, leading
to a loss of histone acetylation and acquisition of histone
H3K9 dimethylation and heterochromatin protein 1 (HP1).
PRDM1 binding also blocks IRF8-mediated activation depen-
dent on the PU.1/IRF composite element. Together these find-
ings reveal themechanisms regulating CIITA and, thus, antigen
presentation in DCs, demonstrating that PRDM1 and IRF8/
PU.1 counter-regulate expression. The activity of PRDM1 in
silencing all three cell type-specificCIITApromoters places it as
a central regulator of antigen presentation.
Dendritic cells (DC)2 are primary sentinels of the immune
system, recognizing pathogens, responding to inflammation,
and providing activation signals to immune effector cells (1).
DCs reside in peripheral tissues such as the skin as well as in the
spleen and lymph nodes where they survey the environment for
pathogens. DCs can also migrate from peripheral tissues to the
lymph node upon encounter with pathogens to facilitate anti-
gen presentation to T cells. Recent studies have revealed that
DCs comprise multiple subsets with both specialized and over-
lapping functions and tissue distribution (2). PlasmacytoidDCs
(pDC) are unique in the ability to secrete large amounts of
Type-I interferon and have lymphoid characteristics. Conven-
tional DCs (cDC) encompass the other subtypes including
monocyte-derived DCs and are the predominant type detected
in the periphery. Encounter with pathogen or inflammatory
stimuli induce cDCs to undergo maturation and increase anti-
gen presentation. This is reflected in increased cell surface
expression ofmajor histocompatibility complex class II (MHC-
II) and co-stimulatory molecules as well as secretion of TH1- or
TH2-inducing cytokines (3, 4).
MHC-II expression is tightly regulated during DC develop-
ment and maturation (3, 5–7). Immature DCs have highly
active antigen processing machinery; however, antigen presen-
tation is limited by the low level of antigen-bound MHC-II
located on the cell surface. The expressed MHC-II molecules
accumulate in peptide loading compartmentswithin the imma-
tureDCs, and those thatmigrate to the cell surface are ubiquiti-
nated by the E3-ligase MARCH1, which promotes endocytosis
and turnover (8, 9). ImmatureDCs upon receiving amaturation
signal such as Toll-like receptor engagement with pathogen-
associatedmolecules switch from antigen processing to antigen
presentation facilitated in part by the down-regulation of
MARCH1 (10). This is paralleled by a cessation of newMHC-II
synthesis to fix the presentation of antigen captured at the time
of pathogen recognition. Thus, althoughMHC-II expression is
increased on the cell surface upon maturation, the transcrip-
tion of MHC-II is silenced.
CIITA is a transcriptional co-activator that acts as a master
regulator of MHC-II gene expression (11, 12). CIITA is
required for MHC-II expression in DCs and B cells as well as
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cytokine-induced expression in other cell types (13–16). Loss of
CIITA either in cells derived from bare lymphocyte syndrome
patients or in CIITA knock-out mice results in a near complete
loss of MHC-II (15, 17–19). The CIITA gene is tightly con-
trolled at the level of transcription and utilizes three distinct
promoters each transcribing a unique first exon (20). Tran-
scription of CIITA from promoter I (CIITApI) is restricted to
cells of the myeloid linage including cDCs and macrophages.
CIITA promoter III (CIITApIII) is active primarily in cells of
lymphoid lineage including B and T cells, although expression
can also be detected in DCs. CIITApIV is responsive to IFN in
non-hematopoietic cells. Mice with targeted deletion of either
CIITApIV or both CIITApIV and CIITApIII confirm that CII-
TApI is functionally sufficient for CIITA expression in mye-
loid-derived DCs and macrophages, whereas CIITApIII is
required for expression in B cells (6, 21). pDCutilize CIITApIII,
not CIITApI, consistent with their lymphoid phenotype (6).
The CIITApIII and CIITApIV promoters have been well
characterized. CIITApIII is regulated in B cells through five
elements that recruit NF1, Oct1, CREB/ATF, AML2, IRF4, and
PU.1 (22–24). The IRF4 and PU.1 factors bind at site C, which
represents an Ets-IRF composite element (EICE). Recently,
PU.1 binding at a distal enhancer located 11 kb upstream of
CIITApIII was also shown to be required for CIITApIII activity
in B cells (25). CIITApIV transcription depends on IFN-in-
duced STAT1 and IRF1 binding at its proximal promoter (26–
28). PU.1 also has a role at CIITApIV in mast cells (29).
Silencing of CIITA and, thus, MHC-II is also tightly regu-
lated. CIITA silencing during B cell to plasma cell differentia-
tion has been directly linked to the transcriptional repressor
PRDM1 (Blimp-1) (30, 31). PRDM1 is required for B cell to
plasma cell differentiation and influences T cell homeostasis
and differentiation into effector T cells (32). In both cases
PRDM1 is part of a negative feedback loop with BCL6 (33). In
addition, we have recently shown that PRDM1 is expressed in
natural killer cells, where it attenuates NK activation (34).
PRDM1 can also be induced by proteasome inhibitor treatment
in mantle cell lymphoma and contributes to the apoptotic
response (35). PRDM1 functions by binding to DNA and serves
as a scaffold to recruit chromatin-modifying enzymes, specifi-
cally the histone deacetylase HDAC2, the histone H3 lysine 9
dimethyltransferase G9a, and the histone H3 lysine 4 demethy-
lase LSD1 (36–38). Each of these chromatin-modifying
enzymes mediates changes associated with inhibition of gene
transcription. The PRDM1 DNA binding site consensus has
overlapping homology with the IRF consensus (39). At the CII-
TApIV promoter, PRDM1 can compete with IRF1, whereas at
CIITApIII, PRDM1 binds the EICE element at site C (30, 40).
Thus, PRDM1 can suppress transcription of its target promot-
ers though displacement of a required IRF factor as well as
inducing multiple chromatin structure changes. In addition to
its role in suppressing CIITApIII during plasma cell differenti-
ation, PRDM1 also suppresses IFN-mediated activation of
CIITApIII and CIITApIV in B cells (40, 41).
The factors activating or repressing CIITApI remain
unknown. Ablation of IRF8 inmice inhibits CD8 DCdevelop-
ment and prevents expression from CIITApI, although
whether this is a direct or indirect effect was not known (42).
Landmann et al. (5) revealed loss of CIITA transcription during
cDC maturation induced by multiple stimuli. The mechanism
was not investigated, but a global loss of histone acetylation
across all of the CIITA promoters was observed. LPS suppres-
sion of CIITA in cDC requires an intact MyD88-dependent
pathway utilizing ERK and p38MAPK signaling (43). Recently,
conditional knock-out of PRDM1 in hematopoietic and endo-
thelial cells was shown to disrupt DC development (44).
PRDM1 expression increased in murine bone marrow-derived
cDC upon receiving maturation signals. This induction
required p38 MAPK and NFB and directly affected transcrip-
tion of IL-6 andMCP-1 (Ccl2). This presents the possibility that
PRDM1 may also affect CIITA regulation in cDCs.
In this report we define the transcription factors required for
CIITA transcription in cDC and show that PU.1 and IRF8 syn-
ergize to promote promoter assembly and activate transcrip-
tion. We also now link the mechanism of CIITA silencing in
cDC to direct PRDM1 recruitment at the promoter followed by
chromatin remodeling and disassembly of the promoter.
EXPERIMENTAL PROCEDURES
Human DC Isolation—Leukocyte buffy coats were obtained
from normal donors (Southwest Florida Blood Bank). Periph-
eral blood monocytic cells were isolated by sedimentation in
Ficoll-Paque (AmershamBiosciences) followed by adhesion for
1 h at 37 °C. Non-adherent cells were removed by gentle wash-
ing. Purity of monocytes was greater than 90% as assessed by
fluorescence-activated cell sorting (FACS) analysis for CD14
(eBioscience). Differentiation into DCs was initiated by the
addition of granulocyte-macrophage colony-stimulating factor
(1000 units/ml, Roche Applied Science) and IL-4 (5 ng/ml,
Roche Applied Science) in RPMI supplemented with 10% heat-
inactivated fetal bovine serum (HyClone). Cytokines were
replenished every other day (days 2, 4, and 6) by removing half
of the medium and adding back fresh medium with 2 cyto-
kines. On day 3 or 7, non-adherent cells were collected bymod-
erately vigorous aspiration and analyzed. Maturation was
induced by the addition of either LPS (10 ng/ml, Sigma) or
macrophage-conditioned medium at a final concentration of
50% v/v on day 7 as described (45). The human monocytic cell
line THP-1 was cultured in RPMI containing 10% heat-inacti-
vated fetal bovine serum and 100 IU/ml streptomycin and
penicillin.
Mouse DC Isolation—Mice DCs were obtained from 6–10-
week-old homozygous Irf8/ and IRF8/ mice with a
C57BL/6 background as previously described (42) using recom-
binant human Flt3L (10 ng/ml, Pepro Tech) culture system.
After 9 days in culture, non-adherent cells were harvested by
gentle aspiration and separated on MACS (Miltenyi Biotec)
with CD11c antibody-conjugated beads.
Flow Cytometry—DCs phenotype was monitored by cell sur-
face-staining. Cells at the time period indicated in supplemen-
tal Fig. 1a were harvested, counted, and stained with FITC- or
phosphatidylethanolamine-conjugated antibodies for CD14,
CD1a, CD11C, CD83, CD86, and HLA-DR for human and
CD8, CD40, CD80, and Flt3 for mice (all from eBioscience).
Samples were collected on a FACSCalibur (BD Biosciences)
and analyzed by FlowJo software (Tree Star). Live cell gates
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were applied on the basis of fluorescencewith propidium iodide
and/or light scatter properties.
RNA Isolation and Quantitative Real-time RT-PCR—Total
cellular RNA was isolated from human DCs with TRIzol rea-
gent (Invitrogen) according to the manufacturer’s instruction.
One g of RNA was DNase-treated using RQ1 DNase (Pro-
mega) followed by first-strand cDNAsynthesis using the iScript
cDNA synthesis kit (Bio-Rad). One-twentieth of the final
cDNA reaction volume was used in each PCR reaction. Quan-
titative real-time PCR analysis was performed using iScript
SYBR Green Master Mix and analyzed using a MyIQ real-time
PCR detection system (Bio-Rad). Primer quality was deter-
mined by single peak onmelt curve and efficiencies between 90
and 100%. Primer sequences are provided in supplemental
Table 1.
In Vivo Genomic Footprinting—In vivo methylation of
human and mouse DCs with dimethyl sulfate and DNA prepa-
rationwere as described previously (22, 46). GenomicDNAwas
digestedwith 100 units of HindIII (New England Biolabs). Liga-
tion-mediated PCR was performed to amplify human and
mouse CIITApI promoter. The sequences of the primers used
for amplification are shown in supplemental Table 1.
DNA Constructs and Transient Transfection—CIITApI pro-
moter regionwas cloned by PCR and subcloned into pGL3basic
using the EcoRI site at position 612 relative to the transcrip-
tion start site and includes 97 bp of exon I. Site-directed
mutagenesis was done by PCR cloning the mutated sequence
into the CIITApI p709 construct. Mutations are the same as
used in the electrophoreticmobility shift assays (EMSAs) below
and are shown in supplemental Table 1. Plasmids and muta-
tionswere confirmed by sequencing. Expression plasmids IRF8,
PRDM1, and dominant negative G9a have been described pre-
viously (36, 47). THP-1 cells (1  106) were transfected by
Superfect reagent (Qiagen) according to the manufacturer’s
instructions. The CIITApI promoter activity was measured
after 48 h per the Dual-Luciferase Reporter Assay System pro-
tocol (Promega). Luciferase readings were done using the
20/20n luminometer (Turner Biosystems). Firefly luciferase
activity was normalized to Renilla luciferase activity in all
experiments.
Electrophoretic Mobility Shift Assay—Human immature DC
nuclear extracts were prepared according to Dignam et al. (48).
Oligonucleotide sequences of probes and competitors are
shown in supplemental Table 1. Gel shift probes were end-
labeled using T4 polynucleotide kinase (New England Biolabs).
Five picomoles of radioactive probe were end-labeled with
[-32P]ATP and purified using mini Quick Spin DNA columns
(RocheApplied Science). 50 pmol of cold competitor probewas
synthesized using the same conditions as above. All binding
reactions included 3 l of nuclear extract, 0.5 mM DTT, and 1
g of poly(dI:dC). Where indicated, 0.2 g of specific antibody
was preincubated with the nuclear extract for 2 h on ice. All
oligonucleotide competitions were done at 50-fold molar
excess. The antibodies specific to PU.1, IRF4, IRF-1, all NFB
subunits, and Sp1 were from Santa Cruz. Antibody to IRF8 was
generated in the Ozato laboratory.
Immunostaining and Confocal Microscopy Analysis—Ma-
ture DCs were harvested, seeded on slides, and fixed with 4%
paraformaldehyde. Cells were permeabilized in 1% Triton X
and methanol (Fisher) to allow intracellular staining. Primary
antibody incubation was carried out for 1 h at 4 °C followed by
three washes with phosphate-buffered saline (PBS) and incuba-
tion with secondary antibodies (Alexa 488 and Alexa 564,
Molecular Probes) for 30 min at room temperature. The anti-
bodies and dilutions used were mouse anti-HLA-DRA (L243,
1:100), goat anti-PRDM1 (Abcam, 1:100), and rabbit anti-G9a
(Upstate, 1:150). After washing in PBS, slides were mounted in
Vector shields with DAPI (Vector Laboratories). Cells were
imaged using a Zeiss LSM 510 confocal microscope and ana-
lyzed by Zeiss LSM software.
Chromatin Immunoprecipitation Analysis—Monocyte-de-
rived DCs were initially treated with 1% formaldehyde for 10
min to ensure cross-linkage followed by cell and nuclear lysis
(50mMTris, pH 8.1, 10mM EDTA, 1% SDS, 0.5 mM PMSF) and
shearing. For each experiment, chromatinwas pooled fromcul-
tured primary DCs derived from four individual donors during
differentiation. Immunoprecipitated chromatin was collected
and washed sequentially with TSE buffer (20 mM Tris, pH 8.1,
50 mM NaCl, 2 mM EDTA, 0.1% SDS, 1.0% Triton X-100) and
LiCl buffer (100mMTris, pH 8.1, 50mMLiCl, 1%Nonidet P-40,
1% sodium deoxycholic acid, 1 mM EDTA). DNA was then
eluted with 50 mM NaHCO3 containing 1% SDS from the pro-
tein A/G beads (Santa Cruz) and reverse-cross-linked at 65 °C
overnight followed by proteinase K treatment. DNA was then
purified via phenol/chloroform extraction and ethanol precip-
itation. For each amplification, 3 l of DNA was analyzed by
quantitative PCR. The amplification primers used are shown in
supplemental Table 1.
RESULTS
In Vivo Genomic Footprinting Analysis Detects Multiple Pro-
tein/DNA Interactions over the CIITApI Promoter in DCs—
MHC-II expression is critical for the antigen presentation func-
tion of DCs, and the cell surfaceMHC-II levels are significantly
increased during DC maturation. Somewhat paradoxically,
mRNA levels for both MHC-II molecules and the master regu-
lator CIITA are markedly down-regulated during maturation
(5). To investigate themechanism of CIITA activation and sup-
pression in DCs, we generated immature DCs from adherent
monocytes isolated from healthy donor peripheral blood and
cultured for 7 days in the presence of granulocyte-macrophage
colony-stimulating factor and IL-4. Subsequent maturation
was induced via LPS or macrophage-conditioned media. Con-
sistent with previous reports, we observed typical DCmorphol-
ogy and surface phenotype as assayed by flow cytometry and
down-regulation of CIITA mRNA isoforms using a variety of
maturation stimuli (supplemental Fig. 1).
In vivo genomic footprinting analysis has been invaluable in
providing unbiased detection of the protein/DNA interactions
occurring in the intact cells with nucleotide resolution (46).We
used this technique to analyze the occupation status of the CII-
TApI promoter within both primary human and mouse DCs
over the region spanning 134 to 115 in human and 86 to
37 in mouse relative to the transcription start site (Fig. 1 and
2). Close association of transcription factors with the DNA can
block or enhance dimethyl sulfate methylation of guanine res-
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idues in vivo. The resulting pattern of guanine methylation is
then compared with that obtained from genomic DNApurified
before dimethyl sulfate treatment. Human immature mono-
cyte-derived DCs display multiple protein/DNA contacts
across the region on both upper and lower strands, which is
consistent with the strong transcriptional activity in these cells
(Fig. 1A, lane 2 versus 1 and lane 5 versus 4). These contacts are
summarized in Fig. 1B and can be clustered into five regions.
Strikingly, many of the observed contacts lie downstream of the
previously reported transcription start site (20). At position7
to 18 are five contacts on a region of high homology to the
consensus EICE. EICE sites cooperatively bind PU.1 and either
IRF4 or IRF8 (49). In addition, 10 in vivo contacts are detected
from position 35 to 55. This region contains closely adja-
cent sequence homologies to Sp1 and NFB binding consen-
suses. Upstream of the transcription start site five contacts
spanning 53 to 33 encompass two putative PU.1 binding
sites of which themore distal sequence has very high homology
to the consensus PU.1 binding element. At position 85 to
59, eight contacts span a putative Sp1 element and a site
labeled Site 1, which has homology to both Ikaros and Oct1
consensus binding elements. Last, a single contact is observed
at position 10. A previous analysis of interactions, which
focused only upstream of the CIITApI transcription start site,
FIGURE 1. In vivo footprint analysis of the human CIITApI promoter in DCs. Immature DCs display multiple protein/DNA interactions that are lost upon
maturation. A, the lower strand of the promoter is shown in lanes 1–3, and the upper strand is shown in lanes 4 –9. Lanes marked cont show the complete guanine
sequencing ladder from in vitro methylated DNA. All other lanes are in vivo methylated DNA samples. Imm represents immature monocyte-derived DCs
cultured with granulocyte-macrophage colony-stimulating factor and IL-4 for 7 days. Mat and LPS represent mature DC cultured with macrophage-condi-
tioned media or LPS (10 ng/ml) for 48 h, respectively. The transcription start site and direction is indicated by a bent arrow and 1, whereas the sequence
position relative to the start site is indicated at the top and bottom of each panel. Residues in immature DCs that are protected or enhanced are indicated by the
open and solid arrows, respectively. Elements are indicated on the left and given a putative factor name as discussed under “Results.” In addition, the E2A and
Ap1 elements previously reported by Landmann et al. (5) are indicated. B, shown is a schematic of in vivo protein/DNA interactions at the human CIITApI
promoter. Protected and enhanced residues are indicated by the open and solid arrowheads, respectively. Putative transcription factor homologies are
indicated with boxes. A comparison of the human and mouse promoters is shown in supplemental Fig. 3.
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reported five contacts on the upper strand (5). Two contacts
(76 and50) are also observed in our analysis but are flanked
by additional contacts. The three other contacts (33, 8, and
7) are adjacent to contacts observed in our analysis. Thus, our
findings are supportive of previous observations and resolve at
high resolution multiple upstream contact points as well as
identifying significant regions of contact downstream of the
transcription start site.
Maturation-induced silencing of CIITApI by exposure to
primary macrophage-conditioned media is accompanied by a
complete loss of protein/DNA interactions in vivo after 48 h
(Fig. 1A, lanes 3 and 6). Previous studies utilizing LPS for 24 h as
the maturation signal did not observe any changes in in vivo
protein/DNA interactions (5). To determine whether primary
macrophage-conditioned media and LPS induce a different
response at the CIITApI promoter, we treated human DCs for
24 and 48 h with LPS and profiled the in vivo protein/DNA
interactions (Fig. 1A, lanes 7–9). After 48 h of LPS treatment all
of the contacts are lost, similar to what we observed in condi-
tioned media. After only 24 h of LPS treatment, the contacts
were present but weaker in intensity (data not shown), suggest-
ing that the promoter was in the beginning stages of disassem-
bly. This is consistent with the previous report done at 24 h but
now reveals that the silencing of CIITApI involves both an ini-
tial inactivation (for example, loss or displacement of a transac-
tivator) followed by a permanent disassembly of the promoter,
as the transcription of CIITA p1 gene has already ceased at 24 h
as shown in supplemental Fig. 1B. TheMHC-II geneHLA-DRA
also disassembles upon DC maturation in accordance with the
loss of CIITA and HLA-DRA transcriptional inactivation (sup-
plemental Fig. 2).
We next determined whether the CIITApI promoter regula-
tory elements are conserved between human and mouse. Pri-
mary murine bone marrow-derived DCs were subjected to in
vivo footprinting across the promoter from86 to37 relative
to the transcription start site (Fig. 2). Multiple contacts were
observed across the entire promoter on both upper and lower
strands. Sequence alignment with the human promoter region
indicates that all of the putative factor binding elements except
for the Site 1 element are conserved betweenmouse and human
(supplemental Fig. 3). Furthermore, the in vivo protein/DNA
interactions in the murine DCs cluster at the same regions of
homology as seen in human DCs.
The EICE element, which is occupied in both human and
murine DCs, recruits IRF8 or IRF4 in a complex with PU.1.
Ozato and co-workers (42) have previously reported that abla-
tion of IRF8 in mice inhibits CD8 DC development and pre-
vents expression from CIITApI. In vivo footprint analysis of
DCs generated from Irf8/mice reveals a nearly complete loss
of occupancy across theCIITApI promoter (Fig. 2, lane 5) com-
FIGURE 2. In vivo footprint analysis of the mouse CIITApI promoter in wild type and IRF8-null DCs. Immature (Imm) bone marrow-derived DCs display
multiple in vivo protein/DNA interactions across the proximal promoter, whereas DCs derived from IRF8-null mice have an unoccupied promoter which can be
rescued by IRF8 reconstitution. A, the lower strand of the promoter is shown in lanes 1 and 2, whereas the upper strand is shown in lanes 3–7. Lanes are marked
as in Fig. 1A. Lane 5 represents DC generated in vitro from Irf8/ mice and is compared with wild type mouse DCs generated in parallel (lane 4). Lanes 6 and 7
represent in vivo interactions in Irf8/ DC reconstituted with either an empty retroviral vector or a retrovirus expressing IRF8, respectively. Occupancy across
the entire proximal promoter requires IRF8 and can be rescued by IRF8. B, shown is schematic of in vivo protein/DNA interactions at the mouse CIITApI
promoter. Protected and enhanced residues are indicated by the open and solid arrowheads, respectively. Putative transcription factor homologies are
indicated with boxes. A comparison of the human and mouse promoters are shown in supplemental Fig. 3.
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pared with that of the wild type. To determine whether the loss
of promoter occupancy is a direct result of the absence of IRF8
at the promoter or a secondary effect resulting from IRF8
absence during the development of DCs, we reconstituted
Irf8/ DCs with an IRF8 expression vector and then profiled
the in vivo protein/DNA interactions. As shown in lanes 6 and
7, reconstitution of IRF8 restored occupancy across the entire
CIITApI promoter. Concomitantly, transcription of the CII-
TApI gene and surface expression ofMHC-II is up-regulated in
the reconstituted cells (supplemental Fig. 4 and Ref. 42). This
indicates that IRF8 is a key factor in CIITApI transcription and
is necessary for assembly of the entire CIITApI promoter.
Identification of Multiple Regulatory Motifs Necessary for
CIITApI Activation—To identify functional regulatory ele-
ments in CIITApI, we cloned an 809-base pair region spanning
from 709 to 100 of the human CIITApI promoter into a
luciferase reporter construct. Site-directed mutagenesis was
done to disrupt the in vivo indentified elements including the
NFB, the conserved PU.1 site at 53, and both the IRF and
PU.1 sites in the EICE composite element. Because transfection
of primary immature monocyte-derived DCs promotes matu-
ration and precludes analysis, the human monocytic cell line
THP-1 was used as a model cell line. The wild type promoter
was transcriptionally active, whereas mutation of any of the
four sites significantly reduced promoter activity (Fig. 3A). The
results demonstrate that these DNA elements are functionally
important for the transcriptional activation of CIITApI. To
directly address the contribution of factors binding at the EICE
aswell as possible cooperation between PU.1 and IRFs, we tran-
siently co-transfected CIITApI reporter plasmids with expres-
sion plasmids encoding either IRF8 or IRF4. THP-1 cells con-
stitutively express PU.1 but have very low levels of IRF8 and
nearly undetectable levels of IRF4 (50). As shown in Fig. 3B,
overexpression of IRF8 or IRF4 significantly enhances CIITApI
transcriptional activity in THP-1 cells. The dramatic induction
in promoter activity is mediated through cooperative interac-
tionwith the EICE site asmutation of either the PU.1 or IRF half
of the EICE site ablated enhancement by IRF8 and IRF4.
PU.1, IRF8, NFB, and Sp1 Associate with the CIITApI in
Vitro—Toexaminewhether the candidate transcription factors
implicated by the in vivo footprinting directly interact with
their specific binding motif in vitro, we performed EMSAs
using nuclear extracts prepared from primary cultured human
immature monocyte-derived DCs. A probe spanning the tan-
dem PU.1 sites at53 forms two fast migrating complexes that
are both diminished by an antibody to PU.1 but not to Sp1 (Fig.
4A). Binding site competition with either a consensus PU.1 ele-
ment or an unlabeled probe inhibited complex formation,
whereas related consensus sites for C/EBP and NFAT
(nuclear factor of activated T cells) had no effect. Complex for-
mation is also prevented when the probe carries a mutation in
the distal half of the tandem PU.1 homology (lane 8), whereas a
mutation of the proximal half did not significantly prevent
complex formation (lane 9). This suggests that the distal PU.1
site is the dominant binding site required for PU.1 binding in
vitro. This is consistent with its higher homology to the PU.1
consensus and its significant effect on transcriptional activity
seen in Fig. 3. In addition, PU.1 is present in both complexes,
and the upper band may consist of a PU.1 dimer bound at the
tandem PU.1 sites.
A similar EMSA analysis of the region spanning the EICE site
is shown in Fig. 4B. Antibody reactivity indicates that the two
fastestmigrating complexes contain PU.1. The upper of the two
PU.1-containing complexes also is diminished by the IRF8 anti-
body, consistent with it representing the EICE complex. A
slightly slower-migrating complex containing IRF8 is also
detected and may represent a complex with another yet to be
identified Ets family member. The antibody to IRF4 induces a
faint but consistent supershifted band, although none of the
complexes is diminished. This indicates that IRF8 and poten-
tially IRF4 can bind to this element. The slowest migrating
complex is nonspecific. Mutation at the PU.1 site prevents for-
mation of all three specific complexes when used as the probe,
FIGURE 3. Mutational analysis of human CIITApI promoter function dem-
onstrates that PU.1, EICE, and NFB elements are critical for transcrip-
tional activity. A, shown is transient transfection of THP-1 cells with the CII-
TApI-p709 construct and its mutants. Constructs are shown diagrammatically
and numbered: 1, wild type; 2, mutation in the distal (53) PU.1 site; 3, muta-
tion of the IRF homology within the EICE element; 4, mutation of the PU.1
homology within the EICE element; 5, is mutation of the NFB site. The X in the
promoter diagrams indicates the site of the mutation. Data were normalized
with Renilla luciferase activity and represent the average of three experi-
ments with the S.D. shown. Significant estimates for each mutant construct
are compared with the wild type was p  0.005. B, overexpression of IRF8 and
IRF4 enhances CIITApI promoter activity dependent on the EICE element.
CIITApI promoter constructs as indicated on the x axis were co-transfected
with expression constructs of IRF8, IRF4, or a control empty vector into THP-1
cells. IRF8 significantly elevated promoter activity (p  0.029) by at least 7-fold
compared with the vector control, whereas IRF4 induced a lesser activation
(p  0.125). Mutation (mut) of either the PU.1 or IRF homologies within the
EICE element ablated induction by IRF8 and IRF4, demonstrating a depend-
ence on an intact EICE. Data were normalized with Renilla luciferase activity
and represent the average of three experiments with the S.D. shown.
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whereas mutation of the IRF site has minimal effect. This indi-
cates that IRF8 does not bind to the DNA in the absence of
PU.1.
The region spanning the NFB and Sp1 sites was also exam-
ined by EMSAs (Fig. 4C). Oligonucleotide competition and
antibodies against Sp1 as well as individual subunits of NFB
including p50, p52, p65, c-rel, and Rel-B were used to identify
the specific protein-DNA complexes. The slowest migrating
complex contains Sp1 in association with multiple NFB sub-
units with the exception of p52. The fastest migrating complex
is nonspecific. Themiddle complex is not affected by any of the
mutations or antibodies and, thus, may also be nonspecific or
represent binding outside of the Sp1 and NFB motifs.
In Vivo Binding of PU.1, IRF8, NFB, and Sp1 in Immature
DCs and Loss of Association upon Maturation—To further
investigate if these factors are associated with regulatory
regions ofCIITA in vivo, we performed chromatin immunopre-
cipitation (ChIP) experiments using primary human mono-
cyte-derived DC cultures. Using primers specific for the CII-
TApI, CIITApIII, andHLA-DRpromoters, we assessed binding
at various times during the maturation. We observed occu-
pancy of PU.1, IRF4, IRF8, p65, and Sp1 in immatureDCs at the
CIITApI promoter (Fig. 5A). An antibody to NF-Y that is not
predicted to associate with CIITApI did not immunoprecipi-
tate the promoter. We also examined the CIITApIII promoter
as mRNA from this promoter was detected in monocyte-de-
rived DC, and previous in vivo footprinting studies showed that
it was occupied by transcription factors (5). A similar pattern of
occupancy by PU.1, IRF8, IRF4, and Sp1 was detected at the
CIITApIII promoter with the notable absence of p65, consist-
ent with the lack of potential NFB binding sites within this
region (Fig. 5B).
A dramatic loss of factor bindingwas observed at bothCIITA
promoters upon 24 and 48 h of maturation. The specificity of
these protein-DNA interactionswas confirmed by examination
of the HLA-DRA promoter (Fig. 5C). Consistent with previous
findings in other cell types, the HLA-DRA promoter effectively
bound NF-Y but not PU.1, IRF8, IRF4, p65, or Sp1. Binding of
NF-Y decreasedwith the time ofmaturation in parallel with the
loss of transcriptional activity. Thus, maturation-induced loss
of CIITAmRNAexpression ismediated through disassociation
of all transcription activators at the promoter consistent with
the in vivo footprinting results in Fig. 1A. These findings also
reveal that the CIITApI and CIITApIII promoters form highly
similar protein-DNA complexes in DCs. Furthermore, the CII-
TApIII structure in DCs is analogous to that previously
detected in B cells. To determine whether the loss of binding at
CIITApI is due to a loss of expression of these key transcription
factors, we measured protein and mRNA levels of these factors
during maturation (supplemental Fig. 5). Only PU.1 was par-
tially diminished in mature cells, whereas expression of the
other factors remained the same or increased. Thus, the factors
are present in the cell but no longer able to effectively associate
with the promoter.
PRDM1 Expression Is Induced upon DC Maturation and
Coordinated with the Silencing of CIITA—PRDM1 is a potent
transcriptional repressor and has recently been shown to be
required for optimal DC maturation (44). Furthermore, the
PRDM1 recognition sequence is homologous to the core EICE
element, which we have shown to be critical for activation of
FIGURE 4. Identification of PU.1, IRF8, Sp1, and NFB factors binding at the human CIITApI promoter in vitro. EMSAs using nuclear extracts from
immature human DCs and oligonucleotides spanning the tandem PU.1 homologies at 53 base pairs (A), the EICE element (B), and Sp1 and NFB elements (C)
are shown. The relevant region, binding site homologies, and position of mutations are indicated at the bottom of each panel. Reactions in which antibodies
were included are indicated above the lane by an - followed by the antibody specificity. Competitor oligonucleotides were added as indicated above the lanes
at 50 –200 molar excess. In panel A, lanes 8 –10, and panel B, lanes 6 –9, the probe used in the binding reaction was created from the mutant sequence indicated
at the top of the lanes and illustrated at the bottom. ns indicates nonspecific complex. Complete sequence of each oligonucleotide is shown in supplemental
Table 1.
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CIITApI. Thus, we hypothesized that PRDM1 contributed to
the maturation-induced silencing of CIITA expression within
the DC lineage. We fist measured PRDM1mRNA levels at dis-
tinct stages of DC maturation using quantitative real-time-
PCR. In immature human monocyte-derived DCs, PRDM1
mRNA is nearly undetectable at day 3 and minimal after 7 days
in culture (Fig. 6A). Maturation with either LPS or macro-
phage-conditioned media results in a significant increase of
PRDM1 mRNA. We tested several maturation stimuli, and all
are capable of inducing PRDM1 (Fig. 6B). Furthermore, immu-
noblot analysis confirms that PRDM1 protein levels are also
increased duringmaturation (Fig. 6C). Importantly, the kinetics
of PRDM1 expression inversely correlate with CIITA expres-
sion, consistent with a negative regulatory role. Thus, we
hypothesized that PRDM1 may mediate silencing of CIITApI.
PRDM1 Competes for EICE Sites and Nucleates Chromatin-
mediated Silencing of CIITA in Vivo—To assess the ability of
PRDM1 to repress activity of the CIITApI promoter, we uti-
lized gene reporter assays in THP-1 cells. Overexpression of
PRDM1 is sufficient to repress basal expression of luciferase
under control of the wild type CIITApI-p709 promoter by
nearly 70% (Fig. 6D).Mutations introduced into either the PU.1
or IRF portion of the EICE element abrogated basal activity
with no further repression mediated via PRDM1. Overexpres-
sion of IRF8 greatly enhances luciferase activity but is nearly
abolished in the presence of PRDM1. These data demonstrate
that a functional EICE element is required for PRDM1-medi-
ated repression and that competition between PRDM1 and
IRF8 controls CIITApI promoter activity. Importantly, co-
transfection of a dominant negative form of the histone meth-
FIGURE 5. Chromatin immunoprecipitation analysis of the key transcrip-
tion activators at the CIITApI promoter. ChIP analysis of CIITApI (A),
CIITApIII (B), and HLA-DRA was done in monocyte-derived DCs (C) generated
from 12 healthy donors and analyzed as three pools of four donors each.
Immature DCs were grown in granulocyte-macrophage colony-stimulating
factor/IL-4 for the indicated number of days followed by maturation with
macrophage-conditioned media for 24 and 48 h. To account for variability
among the three chromatin pools, percent input was calculated then normal-
ized such that each immature day 3 H4-acetyl sample was set to 1 as shown in
Fig. 7. Error bars represent S.D.. Immunoprecipitating antibodies are indicated
on the x axis; IgG was used as control antibody. Due to the close physical
proximity of the PU.1 elements, the signal obtained with the PU.1 antibody
represents the collective binding to each of the three PU.1 elements.
FIGURE 6. PRDM1 is induced during DC maturation and abrogates IRF8-
mediated activation of CIITApI. A, shown is quantitative real-time-PCR anal-
ysis of PRDM1 mRNA induction during maturation of monocyte-derived DCs,
expressed as -fold induction, relative to day 3. Data represent three inde-
pendent experiments with S.D. shown. Immature DC were analyzed at day 3
(D3) and day 7 (D7). Maturation was induced by LPS or macrophage-condi-
tioned medium as indicated. B, shown is quantitative real-time-PCR analysis
of PRDM1 mRNA induction after 24 h of stimulation using multiple maturation
stimuli as indicated on the x axis. Data are expressed relative to GAPDH and
represent three independent experiments with S.D. shown. C, immunoblot
analysis for PRDM1 in immature and LPS-stimulated monocyte-derived DCs is
shown. D, luciferase reporter assays of CIITApI promoter co-transfected with
PRDM1 and/or dominant negative G9a (DN-G9a) expression constructs is
shown. THP-1 cells were transiently transfected, and luciferase assays were
conducted 48 h post-transfection. Data shown represent luciferase activity
normalized to co-transfected Renilla expression and are the average of three
independent experiments with S.D. shown.
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yltransferaseG9a abrogated the repressive potential of PRDM1,
consistent with our previous report showing a requirement for
G9a catalytic activity for PRDM1-mediated silencing of IFN
(36). Further support of this functional interaction is provided
by the observation that both PRDM1 and G9a localize to the
nucleus and display significant overlap only in mature DCs
(supplemental Fig. 6). The upstream PU.1 element, which has
weak homology to the PRDM1 consensus binding motif, is
not required for PRDM1-mediated repression (supplemen-
tal Fig. 7).
To assess the contribution of PRDM1 tomaturation-induced
silencing of CIITA, we performed additional ChIP analysis in
human monocyte-derived DCs. Upon maturation PRDM1,
G9a and HDAC2 accumulate at the CIITApI promoter (Fig.
7A). Progressive loss of acetylation of both histone H3 and H4
was also observed, consistent with loss of CIITA expression
during maturation (Fig. 7B). Concomitantly, the repressive
marks dimethylated histone H3 lysine 9 and HP1, both
increased upon maturation. As in previous ChIP experiments,
we observed a similar pattern of occupancy at CIITApIII,
although at a lesser extent (Fig. 7, C and D). As expected, no
binding of PRDM1 or G9a was detected at the HLA-DRA pro-
moter, but a loss of histone acetylation and an increase in di-
methylated histoneH3 lysine 9 andHP1was observed, consis-
tent withMHC-II silencing.When combined with the previous
ChIP experiments (Fig. 6), these data suggest a mechanism
whereby CIITA silencing is reinforced epigenetically by altera-
tions in histone modifications, which are nucleated via the
binding of PRDM1.
DISCUSSION
In this report we have provided evidence for counter regula-
tion of CIITAby IRF8/PU.1 and PRDM1during thematuration
of human monocyte-derived DCs. We have identified func-
tional components of the transcriptionally competent CIITApI
in immature DC and demonstrate its disassembly upon matu-
ration. Furthermore, PRDM1 mediates a transition from an
active to a repressed chromatin state, resulting in stable silenc-
ing of CIITA in mature DCs. This work complements the pre-
vious report by Chan et al. (44) and identifies CIITApI as a
novel site of PRDM1-mediated regulation. Importantly,
PRDM1 is now shown to compete with IRF8 for EICE sites and
to regulate all three functional CIITA promoters, suggesting a
coordinate mechanism to controlMHC-II expression inmulti-
ple immune cell lineages.
Numerous transcription factors have been identified that
modulate phenotypic changes associated with DC maturation.
IRF4 and IRF8 are closely related transcription factors that
physically interact with PU.1 to regulate gene expression via
recognition of interferon-responsive sequence element and
EICE sequence elements (49). Both factors function in mono-
cyte differentiation into DC in vitro and regulate both a com-
FIGURE 7. Maturation-dependent accumulation of PRDM1, histone modifying enzymes, and repressive chromatin marks at the CIITA promoters.
Chromatin immunoprecipitation analysis of CIITApI (A and B), CIITApIII (C and D), and HLA-DRA (E and F) promoters are shown. The upper panels display the
changes in repressor binding, whereas the lower panels display changes in histone modifications. Analysis by quantitative PCR is as described in Fig. 5. The
antibodies used for immunoprecipitation are indicated on the x axis. G9a and Suv39h1 are both histone H3 lysine 9 methyltransferases that predominantly di-
or trimethylate, respectively. Data represents 12 healthy donors and are analyzed as three pools of four donors each and normalized such that each immature
day 3 H4-acetyl sample was set to 1. Error bars represent S.D.
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mon set of genes as well as unique targets (51). Our results
suggest that both IRF8 and IRF4 are present in DCs and con-
tribute to CIITA activation during DC differentiation. In our
system IRF8 appears to be functionally dominant, as indicated
by increased luciferase activity and higher levels of binding both
in vivo and in vitro relative to IRF4. Furthermore, a functional
EICE element is required for activation. Accordingly, IRF8
transduction into Irf8/ mice rescues both DC maturation
and expression of MHC-II in a DNA binding-dependent man-
ner (42).
Our data indicate that the p65 NFB subunit and the ubiq-
uitous transcriptional activator Sp1 are components of the
active complex at CIITApI in immature DCs. Contacts were
detected at the putative binding sites for these factors in foot-
printing experiments that were lost upon maturation, and site-
directed mutagenesis of the potential NFB binding residues
abrogated basal CIITApI activity in luciferase reporter assays.
Sp1 has been shown to be required for CD11c expression and
may be an important general activator during DC maturation
(52). However, p65 itself is likely not sufficient for CIITA
expression inDCs asDCmaturation proceeds normally, and no
defects in MHC-II expression are observed when p65/
hematopoietic progenitors are adoptively transferred into
lethally irradiated hosts (53). However, DC development is
severely impaired when both p65 and p50 are simultaneously
knocked out, suggesting that cross-talk and compensatory
mechanisms exists among the multiple NFB subunits. Our
EMSA experiments confirm this, as binding to a probe span-
ning the Sp1/NFB region was markedly diminished in the
presence of antibodies to p50, p65, Rel-B, and Sp-1.
Our results also implicate PU.1 in the regulation of CIITApI.
We identified two functionally important PU.1 sites within
human CIITApI; that is, one upstream of the transcriptional
start site and another immediately downstream of the start site
andwithin the context of an EICE element. Both sites displayed
maturation-dependent changes by in vivo footprinting, bound a
PU.1 site-containing probe in EMSA experiments, and con-
ferred basal activity to CIITApI in luciferase assays. As an inter-
acting partnerwith IRF4/8, PU.1 is known to be required for the
generation of DC. Indeed, ablation of PU.1 diminishes the abil-
ity of bone marrow precursors to develop into either conven-
tional or plasmacytoid DCs (54, 55). Several studies have impli-
cated PU.1 in the regulation of CIITA. B cell-specific CIITA
expression is conferred through PU.1 binding to pIII in con-
junction with E47 and IRF4. In B cells, enforced expression of
both PU.1 and IRF8 is not sufficient to drive CIITApIII expres-
sion, suggesting important lineage-specific differences between
activation requirements of promoter I and promoter III (23).
Recently, PU.1 was shown to bind to a distal regulatory element
11 kb upstream of promoter III, which was required for B cell
CIITA expression (25). PU.1 also regulates inducible CIITA
expression through binding to promoter IV in mast cells in
response to IFN (29). In the latter two reports, PU.1 binding
was also detected at promoter I, albeit at lower levels. Impor-
tantly, in DCs PU.1 appears to function both alone and within
the context of its interacting partner IRF8 by binding to both
PU.1 and EICE sites present within CIITApI.
In response to aMycobacterium tuberculosis-derived lipo-
protein, C/EBP binds to PU.1 sites at pI and pIV to prevent
MHC-II expression in macrophages (56), and lung DCs
infected with Mycobacterium bovis exhibit decreased MHC-II
expression relative to uninfected DCs (57). These observations
suggest that competition for PU.1 sites regulates CIITA expres-
sion. In our EMSA experiments we did not detect binding of
C/EBP to the PU.1 site under non-pathological conditions.
Collectively, these data implicate PU.1 as a critical regulator of
CIITA in a variety of contexts and suggest that competition for
PU.1 sites may have important implications for proper antigen
presentation function during infection.
Given that CIITA mRNA levels decrease upon maturation,
wewere interested in determining the factors involved inmedi-
ating this silencing. PRDM1 has been shown to associate with
DC maturation and lead to transcriptional silencing of Il6 and
Ccl2 (44). IL-6 is a negative regulator of DC maturation and
Il6/ mice have increased numbers of DCs (58). Here we pro-
vide further support for a role of PRDM1 in DC maturation,
identifying CIITApI as a novel direct target of binding. PRDM1
has previously been shown to silence both pIII and pIV inB cells
(30, 31, 40, 59). PRDM1 is well known to control terminal dif-
ferentiation of mature B-cells into antibody-producing plasma
cells, whereas more recent studies have demonstrated that
PRDM1 controls effector functions in both CD4 and CD8 T
cells (60–65). Furthermore, our group has demonstrated that
PRDM1 is involved in the negative regulation of effector cyto-
kine production in human NK cells (34). Thus, regulation of
final effector function appears to be a commonmodality across
numerous immune lineages.
PRDM1 mediates silencing of CIITA in DCs through two
distinct mechanisms. First, PRDM1 can compete with IRF8 for
binding to the promoter. Indeed, we observed reciprocal occu-
pancy of IRF8 andPRDM1at theCIITApI promoterwith kinet-
ics consistentwith silencing. Furthermore, IRF8-mediated acti-
vation of luciferase under the control of CIITApI is completely
abrogated in the presence of PRDM1. PRDM1 has been previ-
ously reported to compete with IRF1/2 for DNA binding in
vitro, but little competition was observed with IRF8 (39). How-
ever, a recent ChIP-on-chip analysis defined AANNGAAA as
the dominant motif among PRDM1-bound target genes in the
U266 myeloma cell line (66). This suggests that in vivo PRDM1
binding site sequences are less restricted and could encompass
many IRF binding factors. Importantly, this motif is present in
CIITApI and bound by PRDM1 in mature monocyte-derived
DCs. Our in vivo footprinting and chromatin immunoprecipi-
tation analysis reveals that 48-h DC maturation results in a
complete loss of the activating factors bound to DNA and large
chromatin changes associated with silencing of CIITApI. How-
ever, at 24 h of maturation the promoter appears to have an
intermediate structure where the factors are mostly bound but
histone acetylation is decreasing (Ref. 5 and data not shown).
This likely explains the larger number of protein-DNAcontacts
identified in our study. Expression levels for all of the activating
factors except PU.1 are either unchanged or increased upon
maturation. Whether this decrease in cellular PU.1 levels con-
tributes to recruitment of PRDM1 to the EICE element remains
to be determined. It is possible that low levels of PU.1 destabi-
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lizes the PU.1/IRF8 complex and favors PRDM1 binding over
IRF8 at the EICE site.
Silencing of CIITA is further reinforced by a second mecha-
nism; that is, the recruitment of chromatin-modifying enzymes
by PRDM1. Previous reports have demonstrated the loss of his-
tone acetylation across the CIITApI region during DCmatura-
tion (5). We now show that CIITApI in DCs is silenced via
recruitment of G9a and HDAC2 by PRDM1 analogous to post-
induction silencing of IFN upon polyI:C stimulation (36). G9a
catalyzes the dimethylation of histone 3 lysine 9, a histonemod-
ification known to be associated with silencing of euchromatic
genes (67). Our results demonstrate that catalytic activity of
G9a is required for silencing as a dominant negative form
of G9a, nearly eliminated PRDM1-mediated suppression of
CIITApI in reporter assays. Furthermore, HP1, which binds
methylated histone H3 lysine 9, accumulates to further con-
dense the chromatin in this region. Thus, PRDM1 both com-
petes for sites required for activation and recruits histonemod-
ifiers to nucleate a transition from accessible to inaccessible
chromatin.
Several aspects of PRDM1 function in DC await elucidation.
It will be important to identify other targets of PRDM1 regula-
tion within the DC lineage. Both Il6 and Ccl2 have been previ-
ously identified as PRDM1 targets, whereas we show here that
PRDM1 binds both CIITApI and pIII. Thus, PRDM1 regulates
two essential functions of DCs; that is, cytokine production and
antigen presentation. Presumably, PRDM1 will regulate both
unique DC-specific and overlapping sets of target genes. Addi-
tionally, PRDM1 is reciprocally expressed with the transcrip-
tional repressor Bcl6 and forms a negative feedback loop where
each represses the transcription of the other (33). Several exam-
ples exist within B and T cells whereby Bcl6 is expressed before
PRDM1 and is silenced concomitantly with PRDM1 induction.
This antagonistic expression pattern contributes to differenti-
ation of both plasma cells and T follicular helper cells. Bcl6 has
been shown to be down-regulated upon maturation of mono-
cyte-derived DC (68); however, the functional interplay
between these two transcriptional repressors in DCs has not
been characterized. Finally, pDCs differmarkedly from cDCs as
they continually transcribe MHC-II genes even after antigen
encounter (69, 70). CIITA expression in this subset is driven
primarily by CIITApIII. It will be important to profile the
expression and activity of PRDM1 in pDCs to determine
whether these cells fail to induce PRDM1or utilize an unknown
mechanism to alter PRDM1 function at CIITA. The findings in
this report now provide detailed characterization of the factors
regulating CIITA in cDCs. Through the dedicated function of
CIITA in controlling MHC-II expression, this reveals the
mechanisms behind antigen presentation in cDCs.
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